| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| US27955709P | 2009-10-20 | 2009-10-20 | |
| US61/279,557 | 2009-10-20 | 
| Publication Number | Publication Date | 
|---|---|
| WO2011049625A1true WO2011049625A1 (en) | 2011-04-28 | 
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| PCT/US2010/002804WO2011049625A1 (en) | 2009-10-20 | 2010-10-19 | Method for aflatoxin screening of products | 
| Country | Link | 
|---|---|
| WO (1) | WO2011049625A1 (en) | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes | 
| US3969287A (en) | 1972-12-08 | 1976-07-13 | Boehringer Mannheim Gmbh | Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier | 
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides | 
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands | 
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands | 
| US4247642A (en) | 1977-02-17 | 1981-01-27 | Sumitomo Chemical Company, Limited | Enzyme immobilization with pullulan gel | 
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units | 
| US4301144A (en) | 1979-07-11 | 1981-11-17 | Ajinomoto Company, Incorporated | Blood substitute containing modified hemoglobin | 
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation | 
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer | 
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives | 
| US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) | 
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol | 
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids | 
| WO1990005719A1 (en) | 1988-11-23 | 1990-05-31 | British Bio-Technology Limited | Hydroxamic acid based collagenase inhibitors | 
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time | 
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system | 
| WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production | 
| EP0606046A1 (en) | 1993-01-06 | 1994-07-13 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids | 
| JPH08176070A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Didepside derivative and PI3 kinase inhibitor | 
| JPH08175990A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | PI3 kinase inhibitor and method for producing the same | 
| WO1996027583A1 (en) | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives | 
| WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors | 
| WO1997015658A1 (en) | 1995-10-26 | 1997-05-01 | Ludwig Institute For Cancer Research | Wortmannin phosphoinositide 3-kinase interaction site | 
| EP0780386A1 (en) | 1995-12-20 | 1997-06-25 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors | 
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives | 
| WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases | 
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives | 
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives | 
| WO1998033768A1 (en) | 1997-02-03 | 1998-08-06 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives | 
| WO1998034918A1 (en) | 1997-02-11 | 1998-08-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives | 
| WO1998034915A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases | 
| WO1999002514A2 (en) | 1997-07-08 | 1999-01-21 | Bristol-Myers Squibb Company | Epothilone derivatives | 
| WO1999029667A1 (en) | 1997-12-05 | 1999-06-17 | Pfizer Limited | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | 
| EP0931788A2 (en) | 1998-01-27 | 1999-07-28 | Pfizer Limited | Metalloprotease inhibitors | 
| WO1999052910A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | Bicyclic hydroxamic acid derivatives | 
| WO1999052889A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides | 
| US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones | 
| JP2001247477A (en) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | Antitumor agent | 
| WO2001081346A2 (en) | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta | 
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives | 
| WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase | 
| WO2003034997A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase | 
| WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation | 
| US6608056B1 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd | Fused heteroaryl derivatives | 
| WO2004007491A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives | 
| WO2004006916A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility | 
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents | 
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis | 
| US20040053946A1 (en) | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method | 
| EP1417976A1 (en) | 2001-07-26 | 2004-05-12 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect | 
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives | 
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor | 
| WO2006046035A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds | 
| US20060115824A1 (en)* | 2004-04-15 | 2006-06-01 | Institute For Environmental Health, Inc. | Trend analysis and statistical process control using multitargeted screening assays | 
| US20060270673A1 (en) | 2003-04-24 | 2006-11-30 | Merck & Co., Inc. | Inhibitors of akt activity | 
| WO2007042810A1 (en) | 2005-10-11 | 2007-04-19 | Ludwig Institute For Cancer Research | Pyrimidine derivatives for the treatment of cancer | 
| US20080039459A1 (en) | 2006-04-26 | 2008-02-14 | Plramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use | 
| US20080076768A1 (en) | 2006-04-26 | 2008-03-27 | Piramed Limited | Pharmaceutical compounds | 
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use | 
| WO2008073785A2 (en) | 2006-12-07 | 2008-06-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use | 
| US7534584B2 (en)* | 2004-08-06 | 2009-05-19 | Institute For Environmental Health, Inc. | Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents | 
| WO2009105712A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors | 
| WO2009111547A1 (en) | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis | 
| WO2009109867A2 (en) | 2008-03-04 | 2009-09-11 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives | 
| WO2009111531A1 (en) | 2008-03-06 | 2009-09-11 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors | 
| US7589101B2 (en) | 2005-08-16 | 2009-09-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors | 
| US20090234132A1 (en) | 2006-05-23 | 2009-09-17 | Novartis Ag | 5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors | 
| WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use | 
| US20090233950A1 (en) | 2006-03-02 | 2009-09-17 | Frederic Henri Jung | Quinazoline derivatives | 
| WO2009112565A1 (en) | 2008-03-13 | 2009-09-17 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles | 
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use | 
| US20090233926A1 (en) | 2006-09-14 | 2009-09-17 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders | 
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors | 
| WO2009117482A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms | 
| US20090238828A1 (en) | 2004-08-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations for the Treatment of Diseases involving Cell Proliferation | 
| US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer | 
| US20090239847A1 (en) | 2008-03-19 | 2009-09-24 | Ian Bruce | Organic compounds | 
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors | 
| US20090239859A1 (en) | 2008-02-29 | 2009-09-24 | Chua Peter C | Protein kinase modulators | 
| US7595330B2 (en) | 2005-09-06 | 2009-09-29 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds | 
| US7595320B2 (en) | 2005-03-04 | 2009-09-29 | Aventis Pharma S.A. | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | 
| WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy | 
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors | 
| US20090247567A1 (en) | 2008-03-31 | 2009-10-01 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use | 
| US20090247538A1 (en) | 2004-10-25 | 2009-10-01 | Astex Therapeutics Limited | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | 
| US20090247565A1 (en) | 2005-10-21 | 2009-10-01 | Jongwon Lim | Tyrosine Kinase Inhibitors | 
| US7598245B2 (en) | 2003-08-06 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases | 
| US7601718B2 (en) | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases | 
| US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | 
| US20090258852A1 (en) | 2005-07-08 | 2009-10-15 | Arrington Kenneth L | Inhibitors of Checkpoint Kinases | 
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases | 
| US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | 
| US7605160B2 (en) | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors | 
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations | 
| WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase | 
| US20090263397A1 (en) | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy | 
| WO2009129259A2 (en) | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor | 
| US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | 
| US20090270445A1 (en) | 2006-01-18 | 2009-10-29 | Amgen Inc. | Thiazole compounds and methods of use | 
| US20090270430A1 (en) | 2005-10-07 | 2009-10-29 | Exelixix, Inc. | Pyridopyrimidinone Inhibitors of Pl3Kalpha | 
| US20090270621A1 (en) | 2003-08-14 | 2009-10-29 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes | 
| US3969287A (en) | 1972-12-08 | 1976-07-13 | Boehringer Mannheim Gmbh | Carrier-bound protein prepared by reacting the protein with an acylating or alkylating compound having a carrier-bonding group and reacting the product with a carrier | 
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides | 
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands | 
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation | 
| US4247642A (en) | 1977-02-17 | 1981-01-27 | Sumitomo Chemical Company, Limited | Enzyme immobilization with pullulan gel | 
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands | 
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units | 
| US4301144A (en) | 1979-07-11 | 1981-11-17 | Ajinomoto Company, Incorporated | Blood substitute containing modified hemoglobin | 
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives | 
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer | 
| US4670417A (en) | 1985-06-19 | 1987-06-02 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) | 
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol | 
| US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids | 
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system | 
| WO1990005719A1 (en) | 1988-11-23 | 1990-05-31 | British Bio-Technology Limited | Hydroxamic acid based collagenase inhibitors | 
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time | 
| WO1993021259A1 (en) | 1992-04-14 | 1993-10-28 | Cornell Research Foundation Inc. | Dendritic based macromolecules and method of production | 
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives | 
| EP0606046A1 (en) | 1993-01-06 | 1994-07-13 | Ciba-Geigy Ag | Arylsulfonamido-substituted hydroxamic acids | 
| JPH08175990A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | PI3 kinase inhibitor and method for producing the same | 
| JPH08176070A (en) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Didepside derivative and PI3 kinase inhibitor | 
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives | 
| WO1996027583A1 (en) | 1995-03-08 | 1996-09-12 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives | 
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors | 
| WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors | 
| WO1997015658A1 (en) | 1995-10-26 | 1997-05-01 | Ludwig Institute For Cancer Research | Wortmannin phosphoinositide 3-kinase interaction site | 
| EP0780386A1 (en) | 1995-12-20 | 1997-06-25 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors | 
| WO1998003516A1 (en) | 1996-07-18 | 1998-01-29 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases | 
| WO1998007697A1 (en) | 1996-08-23 | 1998-02-26 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives | 
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives | 
| WO1998033768A1 (en) | 1997-02-03 | 1998-08-06 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives | 
| WO1998034915A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases | 
| WO1998034918A1 (en) | 1997-02-11 | 1998-08-13 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives | 
| WO1999002514A2 (en) | 1997-07-08 | 1999-01-21 | Bristol-Myers Squibb Company | Epothilone derivatives | 
| WO1999029667A1 (en) | 1997-12-05 | 1999-06-17 | Pfizer Limited | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | 
| EP0931788A2 (en) | 1998-01-27 | 1999-07-28 | Pfizer Limited | Metalloprotease inhibitors | 
| WO1999052910A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | Bicyclic hydroxamic acid derivatives | 
| WO1999052889A1 (en) | 1998-04-10 | 1999-10-21 | Pfizer Products Inc. | (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides | 
| US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones | 
| JP2001247477A (en) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | Antitumor agent | 
| WO2001081346A2 (en) | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta | 
| US6800620B2 (en) | 2000-04-25 | 2004-10-05 | Icos | Inhibitors of human phosphatidylinositol 3-kinase delta | 
| US6770641B2 (en) | 2000-04-27 | 2004-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives | 
| US7173029B2 (en) | 2000-04-27 | 2007-02-06 | Astellas Pharma Inc. | Fused heteroaryl derivatives | 
| US7037915B2 (en) | 2000-04-27 | 2006-05-02 | Astellas Pharma Inc. | Fused heteroaryl derivatives | 
| US6838457B2 (en) | 2000-04-27 | 2005-01-04 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives | 
| US6608056B1 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd | Fused heteroaryl derivatives | 
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives | 
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives | 
| US6653320B2 (en) | 2000-04-27 | 2003-11-25 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives | 
| US20040053946A1 (en) | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method | 
| EP1417976A1 (en) | 2001-07-26 | 2004-05-12 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect | 
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis | 
| WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase | 
| US20030158212A1 (en) | 2001-10-24 | 2003-08-21 | Teri Melese | Modulators of phosphoinositide 3-kinase | 
| US20030149074A1 (en) | 2001-10-24 | 2003-08-07 | Teri Melese | Modulators of phosphoinositide 3-kinase | 
| WO2003034997A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase | 
| WO2003037886A2 (en) | 2001-10-30 | 2003-05-08 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation | 
| WO2004006916A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility | 
| WO2004007491A1 (en) | 2002-07-10 | 2004-01-22 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused-benzene derivatives | 
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents | 
| US7605155B2 (en) | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | 
| US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | 
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives | 
| US7601718B2 (en) | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases | 
| US20060270673A1 (en) | 2003-04-24 | 2006-11-30 | Merck & Co., Inc. | Inhibitors of akt activity | 
| US7598245B2 (en) | 2003-08-06 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases | 
| US20090270621A1 (en) | 2003-08-14 | 2009-10-29 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors | 
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor | 
| US20060115824A1 (en)* | 2004-04-15 | 2006-06-01 | Institute For Environmental Health, Inc. | Trend analysis and statistical process control using multitargeted screening assays | 
| US7534584B2 (en)* | 2004-08-06 | 2009-05-19 | Institute For Environmental Health, Inc. | Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents | 
| US20090258359A1 (en)* | 2004-08-06 | 2009-10-15 | Institute For Environmental Health | Modular compositing-multiple lot screening protocols for detection of pathogens, microbial contaminants and/or constituents | 
| US20090238828A1 (en) | 2004-08-14 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Combinations for the Treatment of Diseases involving Cell Proliferation | 
| US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | 
| WO2006046040A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds | 
| US20080207611A1 (en) | 2004-10-25 | 2008-08-28 | Plramed Limited | Pharmaceutical compounds | 
| WO2006046035A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds | 
| WO2006046031A1 (en) | 2004-10-25 | 2006-05-04 | Piramed Limited | Pharmaceutical compounds | 
| US20090247538A1 (en) | 2004-10-25 | 2009-10-01 | Astex Therapeutics Limited | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | 
| US7595320B2 (en) | 2005-03-04 | 2009-09-29 | Aventis Pharma S.A. | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | 
| US20090258852A1 (en) | 2005-07-08 | 2009-10-15 | Arrington Kenneth L | Inhibitors of Checkpoint Kinases | 
| US7589101B2 (en) | 2005-08-16 | 2009-09-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors | 
| US7595330B2 (en) | 2005-09-06 | 2009-09-29 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds | 
| US20090270430A1 (en) | 2005-10-07 | 2009-10-29 | Exelixix, Inc. | Pyridopyrimidinone Inhibitors of Pl3Kalpha | 
| WO2007042806A1 (en) | 2005-10-11 | 2007-04-19 | Ludwig Institute For Cancer Research | Pyrimidine derivatives for the treatment of cancer | 
| WO2007042810A1 (en) | 2005-10-11 | 2007-04-19 | Ludwig Institute For Cancer Research | Pyrimidine derivatives for the treatment of cancer | 
| US20090247565A1 (en) | 2005-10-21 | 2009-10-01 | Jongwon Lim | Tyrosine Kinase Inhibitors | 
| US20090270445A1 (en) | 2006-01-18 | 2009-10-29 | Amgen Inc. | Thiazole compounds and methods of use | 
| US20090233950A1 (en) | 2006-03-02 | 2009-09-17 | Frederic Henri Jung | Quinazoline derivatives | 
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors | 
| US20080076768A1 (en) | 2006-04-26 | 2008-03-27 | Piramed Limited | Pharmaceutical compounds | 
| US20080039459A1 (en) | 2006-04-26 | 2008-02-14 | Plramed Limited | Phosphoinositide 3-kinase inhibitor compounds and methods of use | 
| US20090239936A1 (en) | 2006-05-15 | 2009-09-24 | Yoshikazu Sugimoto | Prophylactic and Therapeutic Agent for Cancer | 
| US20090234132A1 (en) | 2006-05-23 | 2009-09-17 | Novartis Ag | 5-phenyl-thiazol-2-yl-urea derivatives and use as pi3 kinase inhibitors | 
| US20090263398A1 (en) | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations | 
| US7605160B2 (en) | 2006-08-09 | 2009-10-20 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors | 
| US20090233926A1 (en) | 2006-09-14 | 2009-09-17 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders | 
| WO2008073785A2 (en) | 2006-12-07 | 2008-06-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use | 
| WO2008070740A1 (en) | 2006-12-07 | 2008-06-12 | F.Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use | 
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors | 
| US20090263397A1 (en) | 2007-07-06 | 2009-10-22 | Buck Elizabeth A | Combination anti-cancer therapy | 
| WO2009105712A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors | 
| US20090239859A1 (en) | 2008-02-29 | 2009-09-24 | Chua Peter C | Protein kinase modulators | 
| WO2009109867A2 (en) | 2008-03-04 | 2009-09-11 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives | 
| WO2009111547A1 (en) | 2008-03-04 | 2009-09-11 | Wyeth | 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis | 
| WO2009111531A1 (en) | 2008-03-06 | 2009-09-11 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors | 
| WO2009112565A1 (en) | 2008-03-13 | 2009-09-17 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-indazoles | 
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use | 
| WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use | 
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors | 
| WO2009117482A1 (en) | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms | 
| US20090239847A1 (en) | 2008-03-19 | 2009-09-24 | Ian Bruce | Organic compounds | 
| WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy | 
| US20090247567A1 (en) | 2008-03-31 | 2009-10-01 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use | 
| WO2009126635A1 (en) | 2008-04-09 | 2009-10-15 | Abbott Laboratories | 2-amino-benzothiazole derivates useful as inhibitors of rock kinases | 
| WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase | 
| WO2009129259A2 (en) | 2008-04-16 | 2009-10-22 | Takeda Pharmaceutical Company Limited | Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor | 
| Title | 
|---|
| "Basic and Clinical Pharmacology", 2003, MCGRAW HILL | 
| "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS | 
| "Goodman and Gilman's The Pharmacological Basis of Therapeutics", 1996, pages: 11 - 16 | 
| "Handbook of Clinical Drug Data", 2002, MCGRAW-HILL | 
| "Principles of Drug Action", 1990, CHURCHILL LIVINGSTON | 
| "Remingtons Pharmaceutical Sciences", 2000, LIPPINCOTT WILLIAMS & WILKINS. | 
| "The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL | 
| ABID ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 24, 2004, pages 294 - 300 | 
| AOUDJIT ET AL., J. IMMUNOL., vol. 161, 1998, pages 2333 - 2338 | 
| B. MARKMAN, ANNALS OF ONCOLOGY ADVANCE ACCESS, August 2009 (2009-08-01) | 
| BACKER JM., BIOCHEM J, vol. 410, 2008, pages 1 - 17 | 
| BENNETT ET AL., J. PHARMACOL. EXP. THER., vol. 280, 1997, pages 988 - 1000 | 
| BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185 | 
| BLOEMEN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 153, 1996, pages 521 - 529 | 
| BLUME- JENSEN P ET AL., NATURE, vol. 411, no. 6835, 2001, pages 355 - 365 | 
| BOWES ET AL., EXP. NEUROL., vol. 119, 1993, pages 215 - 219 | 
| BURGERING ET AL., NATURE, vol. 376, 1995, pages 599 - 602 | 
| CARNERO A, CURR CANCER DRUG TARGETS, vol. 8, 2008, pages 187 - 98 | 
| CHIOSIS ET AL., BIOORGANIC & MED. CHEM. LETT., vol. 11, 2001, pages 909 - 913 | 
| CHOPP ET AL., STROKE, vol. 25, 1994, pages 869 - 875 | 
| CLARK ET AL., NEUROSURG., vol. 75, 1991, pages 623 - 627 | 
| COSIMI ET AL., J. IMMUNOL., vol. 144, 1990, pages 4604 - 4612 | 
| COUSSENS; WERB, NATURE, vol. 420, 2002, pages 860 - 867 | 
| DEMEESTER ET AL., TRANSPLANTATION, vol. 62, 1996, pages 1477 - 1485 | 
| ENGELMAN JA, NAT REV GENET, vol. 7, 2006, pages 606 - 19 | 
| EXPERT OPIN. INVESTIG. DRUGS, vol. 18, no. 9, 2009, pages 1265 - 12 77 | 
| FISHMAN ET AL.: "Medicine", 1985, J.B. LIPPINCOTT CO. | 
| FRASER ET AL., SCIENCE, vol. 251, 1991, pages 313 - 16 | 
| FRUMAN ET AL., ANN REV BIOCHEM, vol. 67, 1998, pages 481 - 507 | 
| GORCZYNSKI; WOJCIK, J. IMMUNOL., vol. 152, 1994, pages 2011 - 2019 | 
| GROSS ET AL., SCIENCE, vol. 218, 1998, pages 703 - 706 | 
| GUTE ET AL., MOL. CELL BIOCHEM., vol. 179, 1998, pages 169 - 187 | 
| HALLAHAN ET AL., PROC. NATL. ACAD. SCI (USA), vol. 94, 1997, pages 6432 - 6437 | 
| HALLORAN ET AL., ARTHRITIS RHEUM., vol. 39, 1996, pages 810 - 819 | 
| HARARI ET AL., ONCOGENE, vol. 19, 2000, pages 6102 - 6114 | 
| HARNING ET AL., TRANSPLANTATION, vol. 52, 1991, pages 842 - 845 | 
| HARTMAN ET AL., CARDIOVASC. RES., vol. 30, 1995, pages 47 - 54 | 
| HASAGAWA ET AL., INT. IMMUNOL., vol. 6, 1994, pages 831 - 838 | 
| HE ET AL., OPTHALMOL. VIS. SCI., vol. 35, 1994, pages 3218 - 3225 | 
| HERROLD ET AL., CELL IMMUNOL., vol. 157, 1994, pages 489 - 500 | 
| HIGUCHI ET AL.: "Prodrugs as Novel Delivery Systems", ASCD SYMPOSIUM SERIES, vol. 14 | 
| HORGAN ET AL., AM. J. PHYSIOL., vol. 261, 1991, pages H1578 - H1584 | 
| ISOBE ET AL., SCIENCE, vol. 255, 1992, pages 1125 - 1127 | 
| KAKIMOTO ET AL., CELL. IMMUNOL., vol. 142, 1992, pages 326 - 337 | 
| KAUFFMANN-ZEH ET AL., NATURE, vol. 385, 1997, pages 544 - 548 | 
| KAWASAKI ET AL., J. IMMUNOL., vol. 150, 1993, pages 1074 - 1083 | 
| KNOERZER ET AL., TOXICOL. PATHOL., vol. 25, 1997, pages 13 - 19 | 
| LEMMON ET AL., TRENDS CELL BIOL, vol. 7, 1997, pages 237 - 42 | 
| MA ET AL., ONCOGENE, vol. 19, 2000, pages 2739 - 2744 | 
| MARTINDALE: "The Extra Pharmacopoeia", 1999, THE PHARMACEUTICAL PRESS | 
| MATTER A., DRUG DISC TECHNOL, vol. 6, 2001, pages 1005 - 1024 | 
| MULLIGAN ET AL., J. IMMUNOL., vol. 154, 1995, pages 1350 - 1363 | 
| MURPHY ET AL.: "Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery", 1997, PENGUIN BOOKS U.S.A., INC. | 
| NAGASE ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 154, 1996, pages 504 - 510 | 
| NAKAO ET AL., MUSCLE NERVE, vol. 18, 1995, pages 93 - 102 | 
| NATHAN T., MOL CANCER THER., vol. 8, no. 1, January 2009 (2009-01-01) | 
| NICHOLSON; ANDERSON, CELLULAR SIGNALLING, vol. H, 2002, pages 381 - 395 | 
| OPPENHEIMER-MARKS ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 1261 - 1272 | 
| OSHIRO ET AL., STROKE, vol. 28, 1997, pages 2031 - 2038 | 
| PAGES ET AL., NATURE, vol. 369, 1994, pages 327 - 29 | 
| PANAYOTOU ET AL., TRENDS CELL BIOL, vol. 2, 1992, pages 358 - 60 | 
| PANES ET AL., GASTROENTEROLOGY, vol. 108, 1995, pages 1761 - 1769 | 
| PARKER ET AL., CURRENT BIOLOGY, vol. 5, 1995, pages 577 - 99 | 
| PHILLIPS ET AL., CANCER, vol. 83, 1998, pages 41 | 
| PHILP ET AL., CANCER RESEARCH, vol. 61, 2001, pages 7426 - 7429 | 
| PIXU LIU, NATURE REVIEWS DRUG DISCOVERY, vol. 8, 2009, pages 627 - 644 | 
| RAMEH ET AL., J. BIOL CHEM, vol. 274, 1999, pages 8347 - 8350 | 
| REMINGTON'S PHARMACEUTICAL SCIENCES, pages 1435 - 1712 | 
| ROMINA MARONE, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1784, 2008, pages 159 - 185 | 
| RUDD, IMMUNITY, vol. 4, 1996, pages 527 - 34 | 
| SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554 | 
| SAWYER, EXPERT OPINION INVESTIG. DRUGS, vol. JJ., 2004, pages 1 - 19 | 
| SCHIMMER ET AL., J. IMMUNOL., vol. 160, 1998, pages 1466 - 1477 | 
| SHAYESTEH ET AL., NATURE GENETICS., vol. 21, 1999, pages 99 - 102 | 
| SIMPSON; PARSONS, EXP. CELL RES., vol. 264, 2001, pages 29 - 41 | 
| STERNMARK ET AL., J CELL SCI, vol. 112, 1999, pages 4175 - 83 | 
| T. W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS | 
| TALENTO ET AL., TRANSPLANTATION, vol. 55, 1993, pages 418 - 422 | 
| TAMIYA ET AL., IMMUNOPHARMACOLOGY, vol. 29, 1995, pages 53 - 63 | 
| TANAKA ET AL., J. IMMUNOL., vol. 151, 1993, pages 5088 - 5095 | 
| VANHAESEBROECK B, TRENDS BIOCHEM SCI, vol. 30, 2005, pages 194 - 204 | 
| VARA ET AL., CANCER TREATMENT REVIEWS, vol. 30, 2004, pages 193 - 204 | 
| VIVANCO ET AL., NATURE REV. CANCER, vol. 2, 2002, pages 489 | 
| VIVANCO; SAWYERS, NATURE REVIEWS CANCER, vol. 2, 2002, pages 489 - 501 | 
| VLAHOS ET AL., J. BIOL. CHEM., vol. 269, no. 7, 1994, pages 5241 - 5248 | 
| WALKER ET AL., MOL. CELL, vol. 6, 2000, pages 909 - 919 | 
| WEGNER ET AL., LUNG, vol. 170, 1992, pages 267 - 279 | 
| WEGNER ET AL., SCIENCE, vol. 247, 1990, pages 456 - 459 | 
| WHITMAN ET AL., NATURE, vol. 332, 1988, pages 664 | 
| YAO ET AL., SCIENCE, vol. 267, 1995, pages 2003 - 05 | 
| ZENG ET AL., TRANSPLANTATION, vol. 58, 1994, pages 681 - 689 | 
| Publication | Publication Date | Title | 
|---|---|---|
| Quevauviller et al. | Certified reference material for the quality control of EDTA-and DTPA-extractable trace metal contents in calcareous soil (CRM 600) | |
| Benoist et al. | Biasing in the galaxy distribution | |
| De Saeger | Determining mycotoxins and mycotoxigenic fungi in food and feed | |
| WO2006026466A3 (en) | Automated seed sampler and methods of sampling, testing and bulking seeds | |
| Vanheule et al. | The compositional mosaic of Fusarium species and their mycotoxins in unprocessed cereals, food and feed products in Belgium | |
| Tittlemier et al. | Sampling of cereals and cereal-based foods for the determination of ochratoxin A: an overview | |
| Schuller et al. | A review of sampling plans and collaboratively studied methods of analysis for aflatoxins | |
| US20120090410A1 (en) | Method for aflatoxin screening of products | |
| WO2011049625A1 (en) | Method for aflatoxin screening of products | |
| WO2002103329A3 (en) | Apparatus and method for determining the dispersibility of a product in particulate form | |
| Sfeir et al. | An evaluation of municipal solid waste composition bias sources | |
| Stroka et al. | Novel sampling methods for the analysis of mycotoxins and the combination with spectroscopic methods for the rapid evaluation of deoxynivalenol contamination | |
| Tittlemier et al. | By-products of grain cleaning: an opportunity for rapid sampling and screening of wheat for mycotoxins | |
| Maestroni et al. | Sampling strategies to control mycotoxins | |
| Coker | Design of sampling plans for determination of mycotoxins in foods and feeds | |
| US20130199287A1 (en) | Auto Micronaire | |
| Haarer et al. | Early enrichment and restitution of the peripheral blood treg pool is associated with rejection-free stable immunosuppression after liver transplantation | |
| Whitaker et al. | Performance of sampling plans to determine aflatoxin in farmers’ stock peanut lots by measuring aflatoxin in high-risk-grade components | |
| Daun et al. | How green is green? Sampling and perception in assessing green seeds and chlorophyll in canola | |
| Gu et al. | Preparation and Certification of High‐Grade Gold Ore Reference Materials (GAu 19‐22) | |
| Falconer et al. | Automated color sorting of hand-harvested Chardonnay | |
| Masoumi et al. | Design, construction and evaluation of an automatic apple grading system | |
| CN106950238A (en) | A kind of Fast nondestructive evaluation and the method for filtering out low cadmium rice or brown rice simultaneously | |
| Morais et al. | The use of light microscopy in a study of extraneous matter and authenticity of guava, strawberry and grape jams | |
| Park et al. | Performance of three pneumatic probe samplers and four analytical methods used to estimate aflatoxins in bulk cottonseed | 
| Date | Code | Title | Description | 
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | Ref document number:10825332 Country of ref document:EP Kind code of ref document:A1 | |
| 122 | Ep: pct application non-entry in european phase | Ref document number:10825332 Country of ref document:EP Kind code of ref document:A1 |